Application of Nanobiotechnology for Early Diagnosis of SARS CoV 2 Infection in the COVID 19 Pandemic
Abstract A most discussed topic of the new decade, COVID 19 is an infectious disease caused by the recently discovered SARS CoV 2. With an exceedingly high transmission rate, COVID 19 has affected almost all the countries in the world. Absent any vaccine or specific treatment, the humanity is left with nothing but the legacy method of quarantine. However, quarantine can only be effective when combined with early diagnosis of suspected cases. With their high sensitivity and unmatched specificity, biosensors have become an area of interest for development of novel diagnostic methods. Compared to the more traditional diagnostics, nanobiotechnology introduces biosensors as different diagnostics with greater versatility in application. Today, a growing number of analytes are being accurately identified by these nanoscopic sensing machines. Several reports of validated application with real samples further strengthen this idea. As of recent, there has been a rise in the number of studies on portable biosensors. Despite the slow progression, certain devices with embedded biosensors have managed to be of diagnostic value in several countries. The perceptible increase in development of mobile platforms has revolutionized the healthcare delivery system in the new millennium. The present article reviews the most recent advancements in development of diagnostic nanobiosensors and their application in the clinical fields. Key points There is no specific treatment for highly transmissible SARS CoV 2. Early diagnosis is critical for control of pandemic. Highly sensitive/specific nanobiosensors are emerging assets against COVID 19.
Applied microbiology and biotechnology